Isconova utilizes its patented Matrix™ technology for the production of immune stimulating adjuvants. Different saponin combinations that form separate matrix structures have been identified and isolated from the Quillaja saponaria stock extract.
Isconova utilize selected Quillaja saponaria fractions to develop modern, multi-purpose, immune-modulating adjuvant products for a broad range of applications within vaccine development, antibody production and immunological research. Isconovas adjuvant technology is based on the matrix complex, a 40 nanometer particle that is formed by mixing Quillaja saponins, cholesterol and phospholipids.
With over 450 published articles and reviews, the Matrix™ and iscom technology is well-established and accepted. The technology is well protected through a number of patents. Several licensing and manufacturing agreements have been signed, and a number of animal vaccines based on the Matrix™ technology are registered and marketed by major animal vaccine corporations. Since 2009 Isconova has initiated projects in the human vaccine market.